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Intramolecular backfolding of the carboxyl-terminal end of MxA
protein is a prerequisite for its oligomerization
Abstract
Mx proteins are large GTPases, which play a pivotal role in the interferon type I-mediated response
against viral infections. The human MxA inhibits the replication of several RNA viruses and is
organized in oligomeric structures. Using two different experimental approaches, the mammalian
two-hybrid system and an interaction dependent nuclear translocation approach, three domains in the
carboxyl-terminal moiety were identified that are involved in the oligomerization of MxA. The first
consists of a carboxyl-terminal amphipathic helix (LZ1), which binds to a more proximal part of the
same molecule. This intramolecular backfolding is a prerequisite for the formation of an intermolecular
complex. This intermolecular interaction is mediated by two domains, a poorly defined region generated
by the intramolecular interaction and a domain located between amino acids 363 and 415.
Co-expression of wild-type MxA with various mutant fragments thereof revealed that the presence of
the carboxyl-terminal region comprising the amphipathic helices LZ1 and LZ2 is necessary and
sufficient to exert a dominant negative effect. This finding suggests that the functional interference of
the carboxyl-terminal region is due to competition for binding of an as yet unidentified cellular or viral
target molecules.
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Mx proteins are large GTPases, which play a pivotal
role in the interferon type I-mediated response against
viral infections. The human MxA inhibits the replication
of several RNA viruses and is organized in oligomeric
structures. Using two different experimental ap-
proaches, the mammalian two-hybrid system and an in-
teraction dependent nuclear translocation approach,
three domains in the carboxyl-terminal moiety were
identified that are involved in the oligomerization of
MxA. The first consists of a carboxyl-terminal am-
phipathic helix (LZ1), which binds to a more proximal
part of the same molecule. This intramolecular back-
folding is a prerequisite for the formation of an inter-
molecular complex. This intermolecular interaction is
mediated by two domains, a poorly defined region gen-
erated by the intramolecular interaction and a domain
located between amino acids 363 and 415. Co-expression
of wild-type MxA with various mutant fragments thereof
revealed that the presence of the carboxyl-terminal re-
gion comprising the amphipathic helices LZ1 and LZ2 is
necessary and sufficient to exert a dominant negative
effect. This finding suggests that the functional interfer-
ence of the carboxyl-terminal region is due to competi-
tion for binding of an as yet unidentified cellular or viral
target molecules.
Mx proteins are interferon-induced GTPases, which are
highly conserved among species and are present in many if not
all vertebrates. Mx proteins belong to a subfamily of large
GTPases that includes dynamin and VPS1 (1, 2). Common
features of these proteins are their high endogenous GTPase
activity and their tendency to form oligomeric structures (3–7).
Although highly conserved in their amino-terminal moiety
comprising the GTP-binding domain, the various members of
the family of dynamin-related GTPases appear to serve differ-
ent cellular functions. Dynamin and VPS1 are involved in
coated vesicle-mediated endocytosis and intracellular protein
trafficking, respectively, while Mx proteins are effectors of the
interferon type I-mediated antiviral function. In particular,
human MxA, a cytoplasmic protein, shows intrinsic antiviral
activity against various negative strand and at least one posi-
tive strand RNA virus (8–16). The molecular mechanism of
action and the viral target molecules remain largely unknown
(for a review, see Refs. 17 and 18).
Mx proteins from interferon type I-treated cells or recombi-
nant Mx from Escherichia coli have been shown to undergo
extensive oligomerization (19–23). In vitro, purified Mx1 is
able to assume two distinct assembly states, which are inter-
convertible depending on the presence or absence of GTP (20).
Similarly, dynamin self-assembles into ringlike structures,
which are converted into helical stacks in the presence of GTP.
These helical structures appear to enable dynamin to wrap
around the neck of membrane vesicles and help pinch them off
from the plasma membrane (4, 5, 24). For Mx proteins, how-
ever, the functional relevance of the oligomer formation and
GTP-dependent assembly states remains elusive. Further-
more, several regions of Mx proteins have been proposed to be
responsible for the oligomerization. These include a highly
conserved region termed self-assembly motif in the amino-
terminal moiety (20) as well as two amphipathic helices at the
carboxyl-terminal end (19). Recently, Melen and Julkunen (22)
reported that, in the case of the human MxB, the 71 carboxyl-
terminal amino acids comprising the two conserved leucine
repeats are responsible for its oligomerization (22).
Using the mammalian two-hybrid transcription system and
an interaction-dependent nuclear translocation approach (25),
we show here that for MxA the proximal leucine repeat is
necessary but not sufficient for oligomerization. Prerequisite
for the oligomerization is the formation of an intramolecular
interaction. In addition, we demonstrate that only MxA mu-
tants containing both carboxyl-terminal leucine repeats are
able to exert a dominant negative phenotype, strongly suggest-
ing that these are required to interact with viral targets.
EXPERIMENTAL PROCEDURES
Construction of pQE30FMxA Plasmids—First, the sequence coding
for the FLAG epitope N-AspTyrLysAspAspAspAspLys-C (26–28) was
inserted adjacent to the six-histidine tag of plasmid pQE30 (Qiagen
GmbH, Hilden, Germany). The MxA cDNA fragments were then fused
in frame at the 39 end of the FLAG sequence. Where necessary, the MxA
cDNA fragments where joined to the FLAG sequence with a short
linker. pQE30FMxA(L612K) and pQE30FMxA(L643K) were generated
by site-directed mutagenesis of pQE30FMxA using the QuickChange™
mutagenesis kit (Stratagene, La Jolla, CA) according the manufactur-
er’s protocol. Deletion of 4 amino acids (D81–84) in the first GTP-
binding motif was achieved by digestion of plasmid pSP65TMxA (29,
30) with SacI and subsequent re-ligation.
Construction of Expression Vectors Encoding GAL4- and VP16-MxA
Fusion Proteins—The various MxA cDNA fragments were inserted in
frame at the 39 end of the sequences coding for the GAL4 DNA binding
domain (G) in pSG424 (31) and the transactivation domain of VP16 (V)
in pAASV19NVP16 (32).
Construction of pQE16FMxA Mutants—For unknown reasons it was
not possible to express MxA protein fragments containing the His tag as
well as the FLAG-epitope in mammalian cell lines. To remove the His
tag, the FMxA cDNA fragments of all pQE30FMxA constructs were
excised and inserted into plasmid pQE16 (Qiagen GmbH). The carbox-
yl-terminal deletion mutant pQE16FMxA-(2–415) was generated by
introducing a stop codon at position 416 of the amino acid sequence of
MxA. For stable expression of the MxA-(577–662) carboxyl-terminal
fragment, the mouse dihydrofolate reductase coding sequence present
in pQE16 was excised and inserted between the sequences coding for
the FLAG epitope and the MxA-(577–662) peptide.
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Construction of pHMG-FMxA Mutants—To generate suitable con-
structs for the expression of the above described MxA variants in mouse
3T3 cells, the different MxA mutant fragments were released from the
parental pQE16 vectors, blunted, and ligated into the unique EcoRV
site of the eukaryotic expression vector pCL642 (33).
Transient Transfection of Swiss 3T3 Cells—The day before transfec-
tion, 1–3 3 105 cells were seeded with 2 ml of complete growth medium
into 35-mm culture dishes and incubated overnight at 37 °C. Transfec-
tions were carried out with 1 mg of plasmid DNA and 10 ml of Unifec-
tin-10 (kindly provided by A. Surovoy, University of Tu¨bingen, Tu¨bin-
gen, Germany) according to the suggestion of the supplier. For the
mammalian two-hybrid transcription system, 0.35 mg each of a GMxA
and a VMxA fusion protein expression vector were mixed with 0.35 mg
of the CAT1 reporter plasmid pG5BCAT (34). The amount of DNA in
solutions prepared for the transfection experiments was checked by
running agarose gels. The cells were incubated at 37 °C for 48 h prior to
analysis.
CAT ELISA—Cytoplasmic extracts were prepared and the amount of
CAT was determined in 50 mg of total protein per sample with a CAT
ELISA (Roche Molecular Biochemicals, Mannheim, Germany), which
was carried out according to the protocol of the manufacturer.
Indirect Immunofluorescence Analysis—Cells grown on 35-mm cul-
ture dishes were fixed by standard procedures (35, 36). FLAG-tagged
MxA proteins were labeled with the monoclonal mouse antibody anti-
FLAG M2 (Integra Biosciences, Lowell, MA) diluted 1:100 in buffer (5%
normal goat serum, 0.01% sodium azide in phosphate-buffered saline),
while nonflagged MxA proteins were labeled with the monoclonal
mouse antibody 5–56 specific for MxA (dilution 1:100). GAL4 and VP16
fusion proteins were labeled with a rabbit polyclonal antiserum diluted
1:100 specific for a yeast GAL4-VP16 (amino acids 411–488) fusion
protein (Upstate Biotechnology Inc., Lake Placid, NY). Immunostaining
was carried out with 1:100 dilutions of rhodamine isothiocyanate-con-
jugated goat antibodies specific for mouse or rabbit immunoglobulins
(Sigma, Buchs, Switzerland).
For indirect double immunofluorescence analysis, infected cells were
labeled with a mixture of monoclonal mouse anti-FLAG M2 antibody
and of a polyclonal rabbit antiserum (dilution 1:500) directed against
influenza A/Turkey virus. The staining was performed with a mixture
of rhodamine isothiocyanate-conjugated goat anti-mouse (1:100) and
fluorescein isothiocyanate-conjugated goat anti-rabbit (1:50) antibod-
ies. Detection of immunostained cells was carried out with a confocal
laser scanning microscope (Carl Zeiss, Oberkochen, Germany) equipped
for data digitalization.
Virus and Infection Procedurs—The virus stock (6.8 3 108 plaque-
forming units/ml) of fowl plague influenza virus FPV-B, strain
Bratislava (37), was prepared from supernatants of virus-infected
Swiss 3T3 cells (8). The Swiss mouse 3T3 cell line was grown in
Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum.
For immunofluorescence analyses of transfected 3T3 cells, 80%-conflu-
ent cell monolayers were infected for 1 h at room temperature with 5
infectious particles of FPV-B per cell, in medium containing 2% fetal
calf serum and 20 mM HEPES, pH 7.3. The virus inoculum was removed
by two washings with phosphate-buffered saline, and the cultures were
incubated for 5 h at 37 °C in Dulbecco’s modified Eagle’s medium
containing 10% fetal calf serum.
RESULTS
The complete coding sequence of human MxA and various
fragments thereof were cloned in frame downstream of the
coding sequences of the GAL4 DNA-binding region (G, amino
acids 1–147) and VP16 transactivating domain (V, amino acids
412–490) of the expression vectors pSG424 (31) and
pAASVN19VP16 (32), respectively. Expression of all fusion
proteins was verified by transient transfection into mouse
Swiss 3T3 cells, followed by immunofluorescence analysis (data
not shown).
The plasmids pGMxA and/or pVMxA were co-transfected
with the CAT reporter plasmid pG5BCAT (34) into Swiss 3T3
cells. The cells were harvested 48 h after infection, and lysates
were prepared. The amount of CAT enzyme present in the
lysates was determined by ELISA. MxA-MxA interaction was
easily detectable, yielding a high amount of CAT enzyme (on
the average 110 pg of CAT/50 mg of protein) comparable to the
positive control consisting of the direct fusion of the V and G
domains encoded by the plasmid pSGVP (126 pg of CAT/50 mg
of protein) (38). The MxA-MxA interaction was shown to be
specific, since co-expression of the VP16 transactivation do-
main with GMxA fusion protein (plasmids pAASV19NVP16
and pGMxA) or the GAL4 DNA binding region with the VMxA
fusion protein (plasmids pSG424 and pVMxA) did not lead to
the activation of the CAT reporter gene (data not shown).
Oligomerization of MxA Is Mediated by the Carboxyl-termi-
nal Half of MxA—In order to identify regions in MxA required
for the interaction various mutants with progressive deletions
from the amino-terminal or carboxyl-terminal end of MxA were
constructed and tested for interaction. The interaction capacity
of each MxA fragment was assessed by expressing it as GAL4
and VP16 fusion protein (exceptions are indicated in the text).
The data shown in Figs. 1 to 3 represent the mean values of at
least six independent transfection experiments and all CAT
ELISAs were carried out in duplicate. We have observed little
variation of the amount of CAT produced between individual
transfection experiments using the same constructs (normally
less than 10%). As shown in Fig. 1, the entire carboxyl-terminal
moiety of MxA (MxA-(363–662)) is required for the MxA-MxA
interaction. Deletion of 88 amino acids or more from the car-
boxyl-terminal end in both partners (MxA-(2–574)) led to the
complete abrogation of the interaction while deletion of the
entire amino-terminal half (MxA-(363–662)) had no effect.
However, further deletions into the carboxyl-terminal moiety
(MxA-(465–662)) destroyed the capability for interaction.
These findings indicate that the MxA oligomerization do-
main(s) reside within the carboxyl-terminal half of the protein.
To test whether disproportionate expression of MxA frag-
1 The abbreviations used are: CAT, chloramphenicol acetyltrans-
ferase; ELISA, enzyme-linked immunosorbent assay.
FIG. 1. The carboxyl-terminal half of MxA mediates homotypic
interaction. Swiss 3T3 cells were cotransfected with pG5CAT and
pairwise combinations of plasmids expressing mutant and wild-type
MxA (white boxes) fused to GAL4 DBD and to VP16 AD (data not
shown). Cell lysates were tested in a CAT ELISA, and the amount of
CAT enzyme measured (CAT SIGNAL) is given as a percentage of the
wild-type MxA-MxA interaction, which is arbitrarily set to 100%. The
data represent mean values of at least six independent transfection
experiments carried out in duplicate. The amino acid sequence of the
mutants is depicted in scale relative to MxA wild-type.
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ments which have the ability to self-assemble into complexes
(MxA and MxA-(363–662)) would lead to a preferential inter-
action with itself thereby efficiently competing the interaction
with other partners, we performed a series of transfection
experiments where the amount of DNA of one interaction part-
ner was kept constant and the amount of DNA of the other
partner was increased up to 8-fold. Increasing amounts of DNA
of one partner resulted in a decrease of the CAT signal (at
maximum 70% reduction at an 8-fold excess of DNA of one
partner). This decrease was independent of whether the inter-
action partner was able to self-assemble or not (data not
shown). The most likely explanation of this finding is that
sequestering of transcription factors (squelching) required for
the expression of the MxA fragments rather than competition
of MxA fragments for interaction is the cause of the observed
decrease of the CAT signal.
The LZ1 Helix Interacts with a More Proximal Region Lo-
cated between Amino Acids 363 and 574—In order to further
define the localization of the interaction domain(s) of MxA,
amino-terminal deletion mutants were pairwise co-expressed
with the corresponding carboxyl-terminal deletion mutants
and assessed for their capability to transactivate the CAT
reporter gene (Fig. 2). As expected, MxA-(2–362) was not able
to interact with MxA-(363–662). The same result was obtained
with MxA-(2–465) and MxA-(465–662). Remarkably, MxA-(2–
574) and MxA-(574–662) clearly were able to interact with
each other (Fig. 2), indicating the existence of two distinct
interaction domains within the carboxyl-terminal half of MxA,
one residing within the 88 carboxyl-terminal amino acids, the
other between amino acid positions 363 and 574.
In this context it is interesting to note that the two leucine
zipper motifs LZ1 and LZ2, originally described by Melen and
co-workers (19), are located within the 88 carboxyl-terminal
amino acids, making them prime candidates for the interaction
domain. To test this possibility we introduced a mutation into
the constructs pGMxA-(574–662) and pVMxA-(574–662) by
site-directed mutagenesis leading to the replacement of the
leucine residue at position 612 to a lysine residue. This muta-
tion destroys the amphipathic character of the helix LZ1 with-
out affecting the overall a-helical structure. Indeed, MxA-
(574–662, L612K) was not able to bind to MxA-(2–574) (Fig. 2),
lending strong support to the hypothesis that the LZ1 helix
constitutes the carboxyl-terminal interaction domain.
In an attempt to better define the localization of the second
interaction domain, MxA-(2–465) was co-expressed with MxA-
(574–662). The fact that the MxA-(2–465) was not capable to
form a complex with MxA-(574–662) suggests that the region
between amino acid positions 465 and 574 may be important
for the interaction (Fig. 2). Since two amphipathic helices lo-
cated between amino acids 423 and 470 and between 495 and
522 are present within this region, a mutation was introduced
into each of them by site-directed mutagenesis to destroy their
amphipathic character. The resulting constructs pGMxA-(2–
574, V458K) and pGMxA-(2–574, I509K) encode GAL4-MxA
fusion proteins where the valine residue at position 458 or the
isoleucine residue at position 509 was replaced by a lysine
residue. However, co-expression of these proteins with VMxA-
(574–662) led only to slight reductions of the CAT enzyme
transactivation, reaching 49% and 90%, respectively, of the
value for MxA-MxA interaction (Fig. 2).
Intramolecular Interaction of MxA Is a Prerequisite for the
Intermolecular Complex Formation—So far, the results ob-
tained can be explained by an intermolecular interaction of two
distinct domains leading to the dimerization or oligomerization
of the protein as suggested by Schumacher and Sta¨heli (23).
However, the data do not exclude the possibility that an in-
tramolecular interaction between the LZ1 motif and the second
interaction domain can occur. To examine whether MxA mole-
cules engage in an intramolecular interaction, MxA variants
comprising both interaction domains were co-expressed with
various MxA fragments containing only one interaction
domain.
As expected, MxA-(363–577) lacking the last 88 amino acids
showed a strong interaction with the fragment MxA-(574–
662), which comprised the 88 carboxyl-terminal amino acids.
However, MxA-(362–662) interacted neither with MxA-(574–
662) nor with MxA-(465–662) (Fig. 3A). Only co-expression of
GMxA-(363–662) with VMxA-(363–662) resulted in the trans-
activation of the CAT reporter gene. Very similar results were
obtained when MxA-(363–662) was replaced by the full-length
MxA (Fig. 3A). These results clearly demonstrate that an MxA
fragment containing only the LZ1 motif is not able to form a
complex with an MxA fragment containing both interaction
domains. However, when the leucine to lysine substitution at
position 612 in the LZ1 motif was introduced into the full-
length protein (MxA(L612K)), interaction with MxA-(574–662)
was restored (Fig. 3A), demonstrating that the intermolecular
interaction of LZ1 with the second interacting domain was
efficiently blocked by a competing intramolecular interaction.
In a second set of experiments, we assessed the capability of
full-length MxA to interact with MxA fragments lacking in-
creasing portions of the carboxyl-terminal region (Fig. 3B).
Surprisingly, co-expression of full-length MxA with MxA pro-
teins lacking 88 (MxA-(2–574)), 197 (MxA-(2–465)), or 247
FIG. 2. Interaction of the LZ1 domain with a more proximal
region. Swiss 3T3 cells were cotransfected with pG5CAT and pairwise
combinations of plasmids expressing mutant and wild-type MxA (white
boxes) fused to GAL4 DBD and to VP16 AD (data not shown). Cell
lysates were tested in a CAT ELISA, and the amount of CAT enzyme
measured (CAT SIGNAL) is given as a percentage of the wild-type
MxA-MxA interaction, which is arbitrarily set to 100%. The data rep-
resent mean values of at least six independent transfection experiments
carried out in duplicate. The amino acid sequence of the mutants is
depicted in scale relative to MxA wild-type. Vertical lines indicate the
location of amino acid substitutions.
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(MxA-(2–415)) amino acids from the carboxyl-terminal end still
led to the transactivation of the CAT enzyme (65%, 97% and
85%, respectively) when compared with the full-length MxA-
MxA interaction (100%). Only when an additional 53 amino
acids from the carboxyl terminus were deleted (MxA-(2–362))
was the interaction destroyed (Fig. 3B). As expected, the frag-
ment MxA-(363–577) was able to form a complex with full-
length MxA corroborating the previous results. Furthermore,
the pivotal role of the LZ1 region in the intermolecular inter-
action was underscored by the results obtained by co-expres-
sion of full-length MxA carrying the leucine to lysine mutation
at position 612 ((MxA(L612K)) with the MxA-(2–465) or MxA-
(363–577) fragment. In both cases CAT enzyme transactivation
was not observed. Unfortunately, it was not possible to exam-
ine the interaction potential of smaller fragments such as MxA-
(363–415) or MxA-(363–465) since, for unknown reasons, we
were not able to express them in various mammalian cell lines.
Taken together, these results are best explained by a model
where the carboxyl-terminal end of a given MxA molecule folds
back on itself and is thereby stabilized by an intramolecular
FIG. 3. The intramolecular interaction is a prerequisite for the intermolecular interaction of MxA. Swiss 3T3 cells were cotransfected
with pG5CAT and pairwise combinations of plasmids expressing mutant and wild-type MxA (white boxes) fused to GAL4 DBD and to VP16 AD
(data not shown). Cell lysates were tested in a CAT ELISA, and the amount of CAT enzyme measured (CAT SIGNAL) is given as a percentage of
the wild-type MxA-MxA interaction, which is arbitrarily set to 100%. The data represent mean values of at least six independent transfection
experiments carried out in duplicate. The amino acid sequence of the mutants is depicted in scale relative to MxA wild-type. Vertical lines indicate
the location of amino acid substitutions.
Oligomerization of MxA32074
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protein-protein interaction. Only when this internal complex is
formed can an intermolecular interaction with a region located
between amino acids 362 and 415 of MxA occur. A prediction
from this model is that the mutant MxA(L612K) would still be
able to interact with MxA through its intact intermolecular
interaction domain but would not be able to form a complex
with itself because the intramolecular interaction cannot be
formed by either partner molecule. As shown in Fig. 3C, this is
indeed the case. Upon co-expression of MxA with MxA(L612K),
high levels of CAT enzyme were detected (70%) whereas
GMxA(L612K) did not interact with VMxA(L612K). Since
MxA(L612K) is not able to interact with itself it is not able to
form homodimers or oligomers and should therefore only exist
as monomers. In an attempt to disrupt the intermolecular
interaction domain located between amino acids 362 and 415,
we introduced a leucine to lysine mutation at position 389 of
MxA. This mutation interrupts the amphipathic character of
an a-helix located between amino acids 371 and 398. However,
this mutation had no effect on the capacity of this mutant to
form a complex with itself or with wild-type MxA (Fig. 3C).
The Region between Amino Acids 362 and 415 Is Required for
the Intermolecular Interaction—In order to further investigate
the intermolecular MxA interaction, the nuclear translocation
assay originally described by Ponten and co-workers (25) was
used. This approach entails co-expression of TMxA, an MxA
variant containing the nuclear localization signal of the SV40
large T antigen at its amino terminus (30), with FMxA mutants
in mammalian cells. Since TMxA accumulates exclusively in
the cell nucleus (30), cytoplasmic MxA mutants able to interact
with TMxA will also be dragged to the nucleus. A series of
plasmids were constructed that directed the expression of MxA
protein moieties carrying the FLAG epitope (26) at their amino
terminus (Table II). In order to stabilize the expression of
MxA-(577–662), the coding sequence of the mouse dihydrofo-
late reductase (D) was cloned in frame between the FLAG tag
and the MxA coding sequence. The resulting protein was des-
ignated FDMxA-(577–662). As eukaryotic expression vector,
the plasmid pCL642 was chosen, which contains the upstream
regulatory region of the mouse 3-hydroxy-3-methylglutaryl co-
enzyme A reductase gene (33).
To assess whether a given MxA protein fragment was able to
interact with TMxA, the corresponding pHMG-FMxA plasmids
were transfected with or without pHMG-TMxA into Swiss
mouse 3T3 cells. After 48 h the subcellular localization of the
FMxA protein fragment was determined by immunofluores-
cence analysis with a monoclonal antibody directed against the
FLAG epitope. As expected, FMxA was able to form a complex
with TMxA leading to its translocation to the nucleus. The
immunofluorescence analysis for FMxA showed the typical
punctate nuclear staining pattern for TMxA when expressed
alone as a control (Fig. 4). Similarly, FMxA-(D81–84), a GTP-
binding mutant lacking four amino acids in the first GTP-
binding consensus element (39), was translocated to the nu-
cleus. When FMxA-(2–576) and FMxA-(2–415) lacking the 86
and 247 carboxyl-terminal amino acids, respectively, were co-
expressed with TMxA, they also accumulated predominantly in
the nucleus, which is indicative for a tight association with
TMxA. In contrast, FMxA-(2–362) lacking 300 carboxyl-termi-
nal amino acids remained in the cytoplasm and was therefore
not capable to form a complex with TMxA. These results are in
complete agreement with the data generated by the mamma-
lian two-hybrid system, corroborating the conclusion that the
region between amino acid positions 362 and 415 is critical for
the intermolecular interaction of MxA. This was further sup-
ported by the results obtained with FMxA-(362–662), FMxA-
(362–626), and FMxA-(362–576), which showed that these pro-
teins accumulated in the nucleus when co-expressed with
TMxA (Fig. 4). In contrast, FDMxA-(577–662) was not able to
interact with TMxA, which was expected, since the LZ1 domain
can only interact with the second intramolecular interaction
domain in trans when the LZ1 domain of the binding partner
has either been deleted or mutated (Table II).
We also tested two MxA mutants carrying single amino acid
substitutions, namely FMxA(L612K) and FMxA(L643K), for
their ability to interact with wild type MxA. The exchange of
the leucine residue at amino acid position 643 with a lysine
residue in MxA(L643K) alters the distribution of charges in the
LZ2 helix, which has been previously shown to be important for
virus specificity (30). Moreover, the same amino acid substitu-
tion at the corresponding position in mouse Mx1 (Mx1(L612K))
completely abrogated its antiviral activity against influenza A
virus (40). When FMxA(L612K) and FMxA(L643K) were co-
expressed with TMxA, they were efficiently translocated to the
nucleus, indicating that the mutations did not affect their
capability to interact with wild-type MxA. This finding is in
agreement with all previous observations of this study and was
expected since the two mutants contain an intact intermolecu-
lar interaction domain (amino acids 362–415).
The 88 Carboxyl-terminal Amino Acids of MxA Are Sufficient
to Confer a Dominant Negative Effect—We next tested whether
expression of distinct MxA protein fragments would lead to an
interference with the function of wild type MxA. For this pur-
pose, cells of a stably transfected Swiss mouse 3T3-MxA clone
were transiently transfected with MxA mutant proteins and
subsequently assayed for their sensitivity to influenza A virus
by double-immunofluorescence analysis. The presence of viral
antigens was examined with a rabbit polyclonal anti-influenza
A virus serum and the FMxA mutants were detected using a
mouse monoclonal anti-FLAG antibody. To assess whether a
given MxA mutant exerted a dominant negative effect, the
percentage of mutant-expressing cells that were infected with
influenza virus was determined (Table I).
The parental 3T3-MxA cell line which expresses physiologi-
cal levels of MxA in virtually 100% of the cells is resistant to
infection with influenza A virus (8). As expected, transfection of
pHMG-FMxA directing the expression of wild-type FMxA had
no influence on the antiviral activity of the endogenous MxA
(9% infected cells). Similarly, the mutants FMxA-(2–576),
FMxA-(2–363), FMxA-(363–626), and FMxA-(362–576) were
not able to interfere with the function of wild-type MxA (Table
I). By contrast, the mutant proteins FMxA-(D81–84), FMxA-
(362–662), and FDMxA-(577–662) exhibited a dominant-nega-
tive phenotype and reversed at least partially the antiviral
block of MxA (79%, 63%, and 37% infected cells, respectively).
In the case of FDMxA-(577–662), the lower percentage of in-
fected cells is most likely due to its low expression level in the
transfected 3T3-MxA cells. The common denominator of these
proteins is that they comprise the carboxyl-terminal region,
which includes the amphipathic helices LZ1 and LZ2. Intrigu-
ingly, the two mutants FMxA-(362–662, L612K), and FMxA-
(362–662, L643K) did not exert a dominant negative effect
upon MxA (12% and 17% infected cells, respectively) strongly
suggesting that both the LZ1 and LZ2 helices have to be intact
in order for the carboxyl-terminal region to exert a dominant
negative effect.
DISCUSSION
One of the common features of Mx proteins is their tendency
to form large aggregates in vitro and in vivo (19–21). Although
many efforts have been undertaken to define the regions that
direct the oligomer formation, this issue is still highly contro-
versial. Furthermore, the functional role of Mx oligomers in the
antiviral activity remains elusive. One group reported the ami-
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no-terminal self-assembly domain of Mx proteins to be impor-
tant for their oligomeric structure (20), while others favor the
involvement of the carboxyl-terminal moiety in such homotypic
interactions (19, 21, 22, 25). In this study, we show that the
carboxyl-terminal moiety of MxA (amino acids 363–662) con-
tains all the structural components necessary to perform ho-
motypic MxA-MxA interactions. Moreover, taking advantage of
the mammalian two-hybrid system, we were able to identify
three domains that appear to play an important role in oli-
gomerization: an amphipathic helix designated LZ1 located at
the carboxyl terminus (amino acids 595–622); a second, less
well defined domain located between amino acids 363 and 574;
and a third region located between amino acids 363 and 415
required for the intermolecular interaction.
First, a region comprising the 88 carboxyl-terminal amino
acids (amino acids 574–662) was found to be required for the
interaction. This region contains two leucine zipper motifs, LZ1
and LZ2, located between amino acids 595 and 622 and be-
tween 640 and 660, respectively, which had been previously
reported to be responsible for the formation of oligomeric struc-
tures (19). However, we observed that, although this carboxyl-
terminal region (amino acids 574–662) was necessary for a
homotypic interaction, it was not sufficient. The carboxyl-ter-
minal region was not able to form a complex with itself but
engaged in an interaction with a more proximal region located
between amino acids 362 and 574. These findings are in line
with results obtained by Schwemmle and co-workers (21), who
demonstrated that the 98 carboxyl-terminal amino acids, re-
sulting from a mild proteinase K treatment of MxA, formed a
FIG. 4. Nuclear translocation of cytoplasmic MxA mutant proteins upon interaction with TMxA. Wild-type and all mutant forms of
MxA proteins contain a FLAG tag at the amino terminus, except for TMxA, whose amino terminus carries the nuclear localization signal. The
FLAG-tagged protein encoding plasmids were transfected into Swiss 3T3 cells either alone or together with pHMG-TMxA, and their subcellular
distribution was monitored by indirect immunofluorescence analysis using the mouse monoclonal antibody M2, specific for the FLAG epitope. The
nuclear localization of TMxA alone (control) was verified using the monoclonal mouse anti-MxA antibody 5–56.
TABLE I
Evaluation of the dominant-negative phenotype of FLAG-tagged MxA
mutants in 3T3-MxA cells infected with influenza virus
Mutant protein Expressing cellscounted
Infected
cells
Uninfected
cells
% %
FMxA wt 244 9 91
FMxA-(D81–84) 136 79 21
FMxA-(2–576) 202 22 78
FMxA-(2–415) 144 11 89
FMxA-(2–362) 144 6 94
FMxA-(362–662) 227 62 38
FMxA-(577–662) 121 37 63
FMxA-(362–576) 118 4 96
FMxA-(362–626) 121 2 98
FMxA(L612K) 116 6 94
FMxA(L643K) 232 7 93
FMxA-(362–662, L612K) 130 12 88
FMxA-(362–662, L643K) 129 17 83
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stable complex with the rest of the protein. Substitution of a
leucine residue with a lysine residue at position 612 (L612K)
destroying the amphipathic character of LZ1 abrogated the
binding capacity of the carboxyl-terminal region, strongly sug-
gesting that LZ1 constitutes the distal interaction domain.
We also attempted to better define the more proximal region
that binds to LZ1. Data obtained with the mammalian two-
hybrid system revealed that the amino-terminal mutant MxA-
(2–465) was not able to interact with the carboxyl-terminal
mutants MxA-(465–662) or MxA-(574–662). This suggests but
does not prove that the second interaction domain is located
between amino acids 465 and 574. It is also possible that this
proximal binding region is located around position 465 and
might be therefore destroyed in the mutants MxA-(2–465) or
MxA-(465–662).
So far, the results obtained could be explained by two differ-
ent models: (a) an intermolecular head to tail interaction be-
tween MxA molecules or (b) an intramolecular interaction
through a back-folding of the carboxyl-terminal region onto the
body of the protein. Indeed, the carboxyl-terminal region was
not able to compete for binding to the second interaction do-
main in trans when the carboxyl-teminal region was also pro-
vided in cis. Even co-transfection of an 8-fold excess of DNA
encoding MxA-(574–662) over DNA encoding full-length MxA
did not lead to a detectable interaction of these two molecules
(data not shown). Only when the intramolecular interaction
was destroyed by mutation of LZ1 in the context of the full-
length MxA protein or the carboxyl-terminal half (MxA-(362–
662)) was interaction in trans observed. These data clearly
indicate that the intramolecular interaction of the proximal
interaction domain with LZ1 was favored over the same inter-
action occurring in trans, making a direct involvement of the
COOH-terminal region in the intermolecular interaction highly
unlikely.
Therefore, if the two identified interaction domains were
engaged in an intramolecular interaction, a third interaction
domain has to be postulated, which could be responsible for the
oligomerization of Mx proteins. Indeed, such an intermolecular
interaction domain, located between amino acids 362 and 415
of MxA, was identified. All MxA mutants containing this region
did form a complex with full-length MxA. A prerequisite for
this interaction is, however, that at least one of the binding
partners is able to form the intramolecular interaction.
These data strongly suggest that only when the carboxyl-
terminal region of MxA containing the LZ1 helix (region 1)
folds back on its proximal interaction domain (amino acids
363–574, region 2) the MxA molecule becomes competent to
engage in a homotypic interaction with a second MxA molecule.
This association is mediated by the intermolecular interaction
domain (amino acids 363–415, region 3) of the second MxA
molecule. Whether the proximal intramolecular interaction do-
main of MxA is directly involved in this intermolecular inter-
action remains to be determined. Since the intermolecular in-
teraction domain (region 3) of the first MxA molecule is not
involved in this dimer formation, interaction with a third MxA
molecule and hence oligomer formation is possible (Fig. 5). This
model also conforms with data obtained from parallel experi-
ments with mouse Mx1 using the same mammalian two-hybrid
system.2 The results of the dissection of murine Mx1 protein
revealed a similar organization of the structural elements that
were of relevance for the Mx1 oligomerization, suggesting that
in both proteins oligomerization may arise by very similar
mechanisms.
Schumacher and Sta¨heli carried out a very similar study
employing the yeast two-hybrid system to identify domains
mediating the oligomerization of MxA (23). They came to the
conclusion that the carboxyl-terminal region can fold back on a
internal more proximal region of the same molecule. Taking
advantage of our MxA(L612K) construct, they also observed
that residue L612 is critical for this interaction. However, they
suggest that the carboxyl-terminal region is directly involved
in oligomerization by interacting with the internal domain of
2 H. P. Hefti, unpublished data.
TABLE II
The 88 carboxyl-terminal amino acids of MxA are necessary and
sufficient to confer a dominant-negative phenotype
FIG. 5. Model of MxA-MxA interaction mediated by the carbox-
yl-terminal region. The model predicts that MxA proteins may exist
in two forms in the cell: an active monomeric and an inactive oligomeric
form. The oligomeric form may represent a stand-by position preventing
the molecules to be active without the presence of the specific target.
After viral infection a cellular or viral target induces the dissociation of
the MxA molecules, allowing them to exert their powerful antiviral
activity. The three regions that co-participate in the intermolecular
protein-protein interactions responsible for oligomerization are de-
picted as white boxes. Region 1 (amino acids 574–662) folds back to the
more proximal region 2 (amino acids 415–573), forming a stable com-
plex. This folding is the prerequisite for the intermolecular interaction
with the region 3 (amino acids 363–415) of another molecule. The
process could continue as shown in the upper part of the figure and give
rise to the formation of large aggregates.
Oligomerization of MxA 32077
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on August 11, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
other MxA molecules. This conclusion is not supported by our
data, which predict that an intramolecular backfolding is a
prerequisite for the formation of oligomers which are mediated
by a domain between amino acids 362–415. The apparent
discrepancy stems from the fact that Schumacher and Sta¨heli
fail to see an interaction between the full-length MxA with the
fragment MxA-(372–599) with the yeast two-hybrid system,
while we clearly observe interaction of MxA with all fragments
comprising the region between amino acids 362 and 415. It is
therefore highly likely that the amino acids located between
position 362 and 372 are critical for the oligomerization.
In the case of human MxB, oligomerization appears to be
mediated by a different mechanism. Melen and co-workers (22)
have recently shown that hetero-oligomerization between the
cytoplasmic 76-kDa MxB protein and the nuclear 78-kDa var-
iant of MxB containing the amino-terminal nuclear localization
signal was directly mediated by the corresponding 71 carboxyl-
terminal amino acids, which include the leucine repeats LZ1
and LZ2.
All available evidence indicates that MxA(L612K) exists in
the form of monomers in the cytoplasm since it is not able to
form homo-oligomeric structures. This is also evident from
immunofluorescence analysis in transfected 3T3 cells, where a
diffuse instead of a punctate staining pattern is observed. This
mutant MxA protein provides us with a very important tool to
evaluate the functional role of Mx proteins in their monomeric
form. Preliminary evidence indicates that MxA(L612K) exhib-
its antiviral activity against influenza A virus despite the ab-
sence of GTP-hydrolyzing activity.3 It has been previously dem-
onstrated by in vitro studies that the GTP binding activity of
Mx1 or MxA protein is sufficient to exert antiviral activity (12).
The putative role of the oligomerization of Mx proteins still
remains elusive. It is certainly intriguing that the Mx homolog
dynamin, which is involved in the endocytosis of synaptic ves-
icles, also forms intramolecular interactions that are involved
in self-assembly of this protein. Moreover, intramolecular com-
plex formation appears to be important for regulating the dy-
namin GTPase activity (41). So far, however, there is no exper-
imental evidence for Mx proteins to be also functionally related
to the dynamin family.
We also analyzed whether MxA mutant proteins lacking
GTP binding and antiviral activity can exert a dominant neg-
ative effect on wild-type MxA. Dominant interfering effects can
be explained either by a direct interaction of an inactive mu-
tant with its functional counterpart or by an interaction of the
inactive mutant with substrates or target molecules of the
wild-type form. The results presented in this study clearly
show that the carboxyl-terminal region (amino acids 576–662)
comprising the LZ1 and LZ2 motifs is both necessary and
sufficient to interfere with the function of wild-type MxA pro-
tein. MxA mutants that were still capable of binding to MxA
but that lacked the carboxyl-terminal moiety were neutral.
MxA protein fragments containing only one of the two carboxyl-
terminal amphipathic helices (LZ1 or LZ2) in an intact form
also were not able to exert a dominant-negative effect. These
findings answered two important questions. First, the forma-
tion of hetero-oligomers between wild-type MxA and inactive
mutants per se was not sufficient to generate a dominant-
negative effect. This finding is consistent with the results ob-
tained by Ponten and co-workers showing that, although the
MxA fragment MxA-(359–572) is able to interact with wild
type MxA, it cannot exert a dominant negative effect (25).
Moreover, it would fit to our model predicting that oligomeric
structures constitute inactive reservoirs of Mx proteins. Sec-
ond, the dominant negative effect is apparently mediated by an
interaction of the carboxyl-terminal moiety with as yet uniden-
tified viral or cellular target proteins. This study clearly dem-
onstrates that the presence of both leucine repeats LZ1 and
LZ2 is necessary for the functional interference to occur.
In order to better understand the molecular mechanism of
the antiviral function of Mx proteins, it will be instrumental to
further characterize the role of these two amphipathic helices
and to identify their targets. Finally, a structural analysis is
necessary to reliably assign the roles of the various segments of
the MxA protein in the intra- and intermolecular interactions.
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